Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.

Kawaguchi, Wakae

Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. [electronic resource] - Cancer science Dec 2007 - 2002-8 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1349-7006

10.1111/j.1349-7006.2007.00624.x doi


Adenocarcinoma
Annexin A5--analysis
Antineoplastic Agents, Phytogenic--pharmacology
Cell Line, Tumor
Dose-Response Relationship, Drug
Enzyme Inhibitors--pharmacology
Female
Humans
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Ovarian Neoplasms--drug therapy
Paclitaxel--therapeutic use
Phosphoinositide-3 Kinase Inhibitors